Does Buspirone Cause Urinary Retention?
Buspirone can cause urinary retention, though it is a rare adverse effect reported in postmarketing surveillance. 1
Evidence from FDA Drug Labeling
The FDA-approved prescribing information for Buspar explicitly lists urinary retention as a rare postmarketing adverse event 1. While not observed in controlled clinical trials, voluntary reports since the drug's introduction have documented rare occurrences of urinary retention among other adverse effects. The FDA labeling also notes that during controlled studies, urinary frequency and urinary hesitancy were infrequent side effects (occurring in 1/100 to 1/1000 patients) 1.
Clinical Context and Mechanism
The mechanism by which buspirone might cause urinary retention is not directly related to its primary pharmacology. Unlike anticholinergic medications (which are well-established causes of urinary retention), buspirone:
- Acts primarily as a 5-HT1A receptor agonist with no significant anticholinergic properties 1
- Has moderate affinity for D2-dopamine receptors 1
- Does not exert the typical sedative or muscle relaxant effects of benzodiazepines 1
Interestingly, research on buspirone's metabolite (1-PP) suggests it may actually have bladder-relaxing properties through alpha-2 adrenergic receptor antagonism, reducing bladder contractions in animal models 2. This makes the urinary retention reports somewhat paradoxical.
Risk Assessment
The risk of urinary retention with buspirone is substantially lower than with medications that have anticholinergic properties. For comparison, guidelines specifically warn that antimuscarinic medications should be used with "extreme caution" in patients with a history of urinary retention 3, while no such specific warning exists for buspirone.
Key Clinical Considerations:
- Frequency: Urinary retention is classified as "rare" (<1/1000 patients) 1
- More common urinary effects: Urinary frequency and hesitancy (infrequent: 1/100 to 1/1000) 1
- No contraindication: Unlike antimuscarinics, buspirone is not contraindicated in patients with urinary retention history
- Postmarketing nature: These reports come from uncontrolled spontaneous reporting, making causality uncertain 1
Practical Recommendations
If prescribing buspirone to patients with benign prostatic hyperplasia or other urinary conditions, monitor for new or worsening voiding symptoms, but this should not be a primary concern when selecting anxiolytic therapy. The risk profile is far more favorable than tricyclic antidepressants or medications with anticholinergic properties, which show much higher odds ratios for voiding dysfunction 4.
In patients who develop urinary retention while on buspirone, consider alternative causes first (particularly if they are on other medications known to cause retention, such as antimuscarinics, tricyclic antidepressants, or certain antipsychotics) before attributing it solely to buspirone 4.